Can you take Halothane with Nubeqa?
1 drug interaction and 9 additional warnings found for the following 2 drugs:
- halothane
- Nubeqa (darolutamide)
Drug interactions
Moderate drug interactions
Moderate:
halothane darolutamide
Applies to: halothane and Nubeqa (darolutamide)
Using darolutamide together with halothane can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
darolutamide Food/Lifestyle
Applies to: Nubeqa (darolutamide)
Food helps with the absorption of darolutamide into the blood stream.
You should take this medication with food as directed.
Disease interactions
8 potential interactions Applies to: 8 conditions, including Arrhythmia, Hypotension, Pseudotumor Cerebri, Liver Disease, and Heart Block.
Arrhythmia
Moderate:
halothane
Halothane has a moderate potential interaction with Arrhythmia.
Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.
Cerebral Vascular Disorder
Moderate:
halothane
Halothane has a moderate potential interaction with Cerebral Vascular Disorder.
Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.
Heart Block
Moderate:
halothane
Halothane has a moderate potential interaction with Heart Block.
Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.
Hypotension
Moderate:
halothane
Halothane has a moderate potential interaction with Hypotension.
Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.
Ischemic Heart Disease
Moderate:
halothane
Halothane has a moderate potential interaction with Ischemic Heart Disease.
Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.
Liver Disease
Moderate:
Nubeqa
The darolutamide in Nubeqa has a moderate potential interaction with Liver Disease.
Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose). No dose reduction is needed for patients with mild hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.
Pseudotumor Cerebri
Moderate:
halothane
Halothane has a moderate potential interaction with Pseudotumor Cerebri.
Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.
Renal Dysfunction
Moderate:
Nubeqa
The darolutamide in Nubeqa has a moderate potential interaction with Renal Dysfunction.
Patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2) who are not receiving hemodialysis have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose). No dose reduction is needed for patients with mild or moderate renal impairment. The effect of end stage renal disease (eGFR <15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.
Report options
More resources
halothane
A total of 420 drugs are known to interact with halothane.
- Halothane is in the drug class general anesthetics.
- Halothane is used to treat Anesthesia.
Nubeqa
A total of 341 drugs are known to interact with Nubeqa.
- Nubeqa is in the following drug classes: antiandrogens, hormones/antineoplastics.
- Nubeqa is used to treat Prostate Cancer.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.